Group structure
6 companies in 4 countries
Serbia1
United Kingdom1
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Loadingโฆ
6 companies in 4 countries
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Every medicine of every company in the group, current ones first.
17 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| Bimatoprost Medicom 0,3 mg/ml oogdruppels, oplossingOogdruppels, oplossing | Bimatoprost | Netherlands | Authorised | 2018 |
| Dotaremยฎ0.5mmol/mL ยท rastvor za injekciju | Gadoteric acid | Serbia | Authorised | 2025 |
| Dotaremยฎ0.5mmol/mL ยท rastvor za injekciju | Gadoteric acid | Serbia | Authorised | 2025 |
| Dotaremยฎ0.5mmol/mL ยท rastvor za injekciju | Gadoteric acid | Serbia | Authorised | 2025 |
| Optiray 300300mg I/mL ยท rastvor za injekciju/infuziju | Ioversol | Serbia | Authorised | 2024 |
| Optiray 300300mg I/mL ยท rastvor za injekciju/infuziju | Ioversol | Serbia | Authorised | 2024 |
| Optiray 350350mg I/mL ยท rastvor za injekciju/infuziju | Ioversol | Serbia | Authorised | 2023 |
| Optiray 350350mg I/mL ยท rastvor za injekciju/infuziju | Ioversol | Serbia | Authorised | 2023 |
| Optiray 350350mg I/mL ยท rastvor za injekciju/infuziju | Ioversol | Serbia | Authorised | 2023 |
| Optiray 350350mg I/mL ยท rastvor za injekciju/infuziju | Ioversol | Serbia | Authorised | 2023 |
| Optiray 350350mg I/mL ยท rastvor za injekciju/infuziju | Ioversol | Serbia | Authorised | 2023 |
| Optiray 350350mg I/mL ยท rastvor za injekciju/infuziju | Ioversol | Serbia | Authorised | 2023 |
| Tobrabact, oogdruppels, oplossing 3 mg/mlOogdruppels, oplossing | Tobramycin | Netherlands | Authorised | 2001 |
| ZIMED 0,3 MG/ML COLIRIO EN SOLUCION0,3 mg/ml ยท Colirio en soluciรณn | Bimatoprost | Spain | Marketed | 2019 |
| Dotaremยฎ0.5mmol/mL ยท rastvor za injekciju | Gadoteric acid | Serbia | Expired | 2021 |
| Dotaremยฎ0.5mmol/mL ยท rastvor za injekciju | Gadoteric acid | Serbia | Expired | 2021 |
| TOBRABACT 3,0 mg/ml COLIRIO EN SOLUCION3 mg ยท Colirio en soluciรณn | Tobramycin | Spain | Suspended | 2001 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Serbia | 13 | 11 | 2 | CompaniesAll medicines |
| Spain | 2 | 1 | 1 | CompaniesAll medicines |
| Netherlands | 2 | 2 | 0 | CompaniesAll medicines |
Also in the registers of Brazil, France, United Kingdom
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Companies are grouped by Prognia from the names regulators publish; not an official corporate structure.
Fuente de la informaciรณn: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: BDPM (ANSM, HAS, UNCAM).
Licence: Licence Ouverte v1.0
Anvisa, https://dados.anvisa.gov.br/dados/CONSULTAS/EMPRESA_FISCALIZACAO_PRODUTO/TA_CONSULTA_CBPF_MEDICAMENTO_DETALHE.CSV; source modified Fri, 15 May 2026 07:52:35 GMT; acquired 2026-10-18T08:23:43.211112+00:00; original factual values retained, no endorsement.
Licence: Brazil federal factual open data, consolidated Decreto 8777/2016 article 4; attribution and third-party exceptions
Fuente de la informaciรณn: Agencia Espaรฑola de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la informaciรณn: Agencia Espaรฑola de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 2 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:48.423930+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
ALIMS, Registar humanih lekova, source 08.10.2026 02:00, downloaded 2026-10-08, https://data.gov.rs/sr/datasets/lekovi-za-upotrebu-u-khumanoj-meditsini/; structured factual adaptation; Serbian Open Data Licence.
Licence: Serbian Open Data Licence (sodl)
Report an error or request removalCorrections from the company itself are welcome.
Keep Medicomโs medicines accurate on Prognia, see how professionals use them and answer what they ask. A 20-minute call, in English.
Book a callWell-known pharmaceutical groups, each with all its companies.